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DEVELOPMENT OF COST-EFFECTIVE
WEB-BASED OUTCOMES RESEARCH STUDIES 
AND DISEASE MANAGEMENT PROGRAMS
Ambegaonkar AJ, Day D
Pfizer, Inc, Alexandria, VA, USA
Innovations in information technology are rapidly chang-
ing the health care market. With more and more clinical
trials being conducted and managed on the web, the In-
ternet provides an opportunity for conducting effective
multi-center outcomes research studies and developing
disease management programs. OBJECTIVES: This re-
search describes the development of a web-driven appli-
cation for ongoing collection, analysis, and reporting of
outcomes research data. In addition, the web application
was developed to gain experience in provision of bench-
marking reports to health care providers conducting dis-
ease management programs. METHODS: Given current
privacy regulations a multi-level security system with er-
ror checking was developed to assure integrity of data en-
tering the system. Through integration of several pro-
gramming languages (Visual Basic Script, Java Script, and
HTML) into web-based active server pages, a method for
immediate data collection, summary, and on-demand re-
porting was successfully developed. The system was de-
ployed remotely via an Internet Service Provider. A pro-
spective multi-site (10) hospital based infectious disease
study of fungal risk and treatment patterns; and a retro-
spective lipid/cardiology clinic based study of patient care
was conducted using the above technology. RESULTS:
For expenditures of less than $1,000, secure web applica-
tions were developed that provided electronic data cap-
ture of all study variables. The customizability of the pro-
gram allowed for developing applications for differing
disease states thereby reducing set-up costs and improving
efficiency. Simultaneous multi-site training and minimal
data entry errors further reduced costs. The applications
also provided real-time reports that enhanced patient-
care and reported practice patterns that highlighted na-
tional and regional variations. CONCLUSIONS: The
success of these studies has demonstrated the utility of
the internet in providing health care practitioners with a
cost-effective tool for efficiently conducting multi-center
outcomes research and disease management. Considering
the increasing popularity and access to the Internet, this
research has significant implications for outcomes re-
search and disease management.
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DOES WHERE YOU LIVE AFFECT IF AND HOW 
YOU DISCOUNT FUTURE COSTS AND 
BENEFITS IN ECONOMIC EVALUATION? 
SHOULD IT?
Faulkner LA1, Gafni A2, O’Brien BJ1
1Centre for Evaluation of Medicines, St Joseph’s Hospital, 
McMaster University, Hamilton, ON, Canada; 2McMaster 
University, Hamilton, ON, Canada
OBJECTIVES: An accepted practice with unresolved is-
sues in economic evaluation is the discounting of future
costs and benefits. Many people conducting evaluations
view discounting as a technical matter and look to guide-
lines for the proper rate. Therefore, we ask three ques-
tions about international guidelines: 1) what discount
rate(s) are recommended; 2) do they differ for costs and
health outcomes; 3) what is the underlying theory for dis-
counting and rationale for the rate(s)? METHODS: We
review recommendations about discounting in interna-
tional guidelines according to underlying theory used to
recommend discounting, suggested rates, rationale for
particular rates, whether a different rate was suggested
for health outcomes, and what literature was cited. RE-
SULTS/CONCLUSION: Australia, Canada, and Ontario
recommend discounting costs and health outcomes at
5%, the US 3%, New Zealand 10%, and the Netherlands
4%, while the UK recommends 6% for costs and 1.5%
for health outcomes. Most countries recognize the con-
troversy, yet remain unconvinced that health outcomes
should be discounted at different rates. While the pri-
mary stated underlying theory for discounting is time
preference, the rationale (if provided) for the particular
rates recommended varies across countries. Most often, it
relies on empirical estimates of government bond rates
and/or notions of international consistency reflecting po-
tentially conflicting principles. Implicit appeals to mea-
sure pure time preference also exist; however, this may
not be measurable if time and health are inextricably
linked. Furthermore, some health outcome measures may
already include individuals’ time preferences potentially
leading to double discounting. Implications will be dis-
cussed.
PMA4
AN ECONOMIC PROOF AND APPLICATION 
THAT FORMULARY RESTRICTIONS WITHIN 
DRUG CLASSES ALWAYS RESULT IN
HIGHER COSTS
Simons WR
Global Health Economics & Outcomes Research, Inc, Short 
Hills, NJ, USA
Pharmaceutical benefit providers use restrictive formular-
ies to control health care expenditures for drugs. One
type of restriction requires the use of one drug before the
use of another drug within the same drug. OBJECTIVE:
Test the hypothesis that restrictive formularies lower ex-
penditures for pharmaceuticals. METHOD: We use ex-
pected utility theory to derive equations for the restrictive
and unrestrictive formulary cases where the equations
take into account effectiveness (i.e., the probability of
attaining treatment goal and not attaining goal), alter-
natives if treatment fails and costs of each scenario. Ad-
ministrative costs are assumed zero. We prove mathe-
matically that restrictive formularies within drug classes
always cost more. Moreover, even if all drugs in the ther-
apeutic class are equal in effectiveness and equal in cost,
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the restrictive formulary will still always be more costly
than the unrestrictive one. We then allow effectiveness
and costs to vary and derive equation to calculate the
cost of a restrictive formulary in those cases. We derive
the equations for patients with various distributions of
baseline severity. Last, we apply the equations and actual
effectiveness and cost data to the case of atypical anti-
psychotics where Ontario and British Columbia Provin-
cial formularies have mandated that risperidone be pre-
scribed before quetiapine or olanzapine. RESULT: The
cost of the restrictive status would range from $0.87–
0.97 per patient per day with mild symptoms treated
with risperidone, $2.65–3.30 for patients with moderate
symptoms and $5.14–5.73 for patients with severe symp-
toms. The range depends on effectiveness rates. Even if
all drug costs were equal and the efficacy rates were all
80 percent, the cost per patient per day for the restrictive
status of quetiapine would be $0.66–0.71, $1.12–1.41,
$1.67–2.26 for risperidone patient with mild moderate
and severe symptoms. CONCLUSION: To our knowl-
edge this is the first proof and practical application. Re-
strictions were removed in both provinces.
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A RISK ADJUSTMENT METHODOLOGY FOR 
CLAIMS DATA
Wilson P, Yuan Y, Dowse BT
IMS Health, Plymouth Meeting, PA, USA
OBJECTIVES: To develop a risk adjusted outcomes mea-
surement system that compensates for the lack of clinical
information in the claims data by dividing diseases into
different stages according to the severity at various stages
of the disease progression and the presence of other con-
ditions and procedures coded in the claims database.
METHODS: The data sources used were Medicare and
a large employer’s claims databases, which covered ap-
proximately 12 million and 130 thousand hospitali-
zations per year respectively. Rigorous data validation
processes were applied to ensure data validity. Our meth-
odology was based on the research completed by JS Gon-
nella, et.al,, (1987) “A Clinically Based Approach to
Measurement of Disease Severity”, sponsored by Na-
tional Center for Health Services Research, which classi-
fied diseases and combinations of diseases into different
stages according to severity. Our risk adjustment system
applied this approach to the principle diagnosis, second-
ary diagnoses and procedures coded in the claims data, to
derive severity measurements for each hospitalization. In
addition, we adjusted for the number of body systems in-
volved, patient age, gender and other factors. Outcomes
measurement included mortality, potentially avoidable
complications, length of hospital stay, total charges and
total cost. For each DRG group, logistic regression and
multiple regression models were developed from the
Medicare claims data to create risk adjusted norms.
Models were checked for statistical and clinical validity.
RESULTS: The model outputs were applied to the large
employer’s claims data to score each patient for each out-
come measurement. The results allowed for multi-dimen-
sional comparisons on quality measurements and re-
source utilization measurements for all the hospitals in
the large employer’s database. CONCLUSIONS: The
uniqueness of our methodology was that it adjusted for
severity of diseases at various stages and combinations of
diseases and number of body systems involved. It pro-
vided a more accurate means for risk adjustment than
currently available.
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THE REDUCTION OF SAMPLE SIZE FOR A
COST-EFFECTIVENESS TRIAL USING A
NEW METHOD: THE EIGHT CASES IN JAPAN
Kamae I, Yanagisawa S, Nakahara N
Kobe University, Kobe, Japan
At ISPOR’s Third Annual European Conference, we pre-
sented a new formula that can naturally extend the tradi-
tional formula for sample-size calculation of a clinical
trial, considering the cost-effectiveness ratios for two reg-
imens A and B. OBJECTIVE: According to the formula,
to explore applicability and validity of such a theoretical
framework in real clinical trials, and then show the bene-
fit which the new formula brings in terms of designing a
prospective cost-effectiveness trial. METHODS: We
searched and reviewed the published Japanese articles
these ten years that reported socioeconomic evaluation of
pharmaceuticals based on a clinical trial for two regi-
mens: a new treatment and an old one. Subsequently we
assessed the applicability and the validity of our formula
in the context of such reviewed articles, and then if the
formula could be applied, we calculated two sample
sizes: considering effect only vs. cost-effectiveness. RE-
SULTS: We reviewed eighteen Japanese articles which
conducted cost-effectiveness analysis using modeling or
retrospective cost evaluation after clinical trials except
one prospective study. Of these eight were selected as ap-
plicable for our formula. In all of them we found that the
sample size for one regimen, considering effect only vs.
cost-effectiveness, can be reduced such as 1534 to 5 at
the best, and 632 to 319 at the worst ratio. CONCLU-
SION: In the eight published Japanese studies, the sample
size of each clinical trial considering effect only could ac-
tually be reduced if such studies are to be designed in ad-
vance as a prospective cost-effectiveness trial considering
the difference of the cost-effectiveness ratios of two regi-
mens.
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CONTROLLING FOR BIASES FROM 
MEASUREMENT ERRORS IN HEALTH 
OUTCOMES RESEARCH USING STRUCTURAL 
EQUATION MODELING
Shi J, McCombs J, Hay J, Nichol M, Chou CP, Hsiao C
University of Southern California, Los Angeles, CA, USA
